VUB neurologist argues for affordability of new Alzheimer’s drug

- EN - NL
The FDA, the American drug watchdog, has recently approved a promising Alzheimer's treatment for reimbursement. This is a game changer for patients: Lecanemab is the first drug that can slow the evolution of the condition. However, its current price in the US is up to 24,700 a year. In the EU too, the cost could be high.
account creation

TO READ THIS ARTICLE, CREATE YOUR ACCOUNT

And extend your reading, free of charge and with no commitment.